Camber Spine announced 1Q19 preliminary proprietary sales results of +22% vs. 1Q18. (Proprietary sales refers to products innovated and owned by the company.)
Growth was largely driven by continuing adoption of SPIRA and ENZA products, which grew +97% vs. the prior year. The company has plans to launch a device for sacroiliac joint repair, an expandable TLIF spacer and custom implant options to bolster its portfolio. Camber Spine anticipates receiving a CE mark for SPIRA later this year.
Camber Spine announced 1Q19 preliminary proprietary sales results of +22% vs. 1Q18. (Proprietary sales refers to products innovated and owned by the company.)
Growth was largely driven by continuing adoption of SPIRA and ENZA products, which grew +97% vs. the prior year. The company has plans to launch a device for sacroiliac joint...
Camber Spine announced 1Q19 preliminary proprietary sales results of +22% vs. 1Q18. (Proprietary sales refers to products innovated and owned by the company.)
Growth was largely driven by continuing adoption of SPIRA and ENZA products, which grew +97% vs. the prior year. The company has plans to launch a device for sacroiliac joint repair, an expandable TLIF spacer and custom implant options to bolster its portfolio. Camber Spine anticipates receiving a CE mark for SPIRA later this year.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
